NWBO — Northwest Biotherapeutics Income Statement
0.000.00%
- $516.80m
- $578.58m
- $1.93m
Annual income statement for Northwest Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.41 | 1.29 | 1 | 1.68 | 1.93 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 32.3 | 89.5 | 53.9 | 71.6 | 62.8 |
Operating Profit | -29.9 | -88.2 | -52.9 | -69.9 | -60.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.8 | -530 | 179 | -105 | -62.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.8 | -530 | 179 | -105 | -62.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.8 | -530 | 179 | -105 | -62.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.8 | -530 | 179 | -105 | -64.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.033 | -0.728 | 0.205 | -0.101 | -0.053 |